FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Empirical Derivation and Prediction of Treatment Trajectories in Harmonized AUD Clinical Trial Datasets. PMID 40700031 · Addict Biol · 2025-Jul 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| An overview of randomized phase III clinical trials of cancer nanomedicines. PMID 40697515 · Cancer Pathog Ther · 2025-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Trastuzumab in early curative breast cancer: A target trial emulation benchmarked against two randomized clinical trials. PMID 40690519 · PLoS Med · 2025-Jul The record describes an observational analysis (target trial emulation) benchmarked against two existing randomized trials (B-31 and N9831). It is not an original formal-result report of a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a time-to-event efficacy endpoint. While it discusses and cites Phase III trials, the report itself does not present the results of such a trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Group-based interventions to reduce gambling involvement among male football fans: a synopsis of findings from a feasibility study. PMID 40690427 · Public Health Res (Southampt) · 2025-Jul 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial. PMID 40686671 · EClinicalMedicine · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Doravirine-based Regimens by Sex and Race: Long-term Results From Three Phase 3 Clinical Trials. PMID 40672760 · Open Forum Infect Dis · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Donanemab exposure-response in early symptomatic Alzheimer's disease. PMID 40667684 · Alzheimers Dement · 2025-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: A Randomized Clinical Trial. PMID 40663622 · Circ Cardiovasc Interv · 2025-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Association of ATP-binding cassette transporter genomic alterations and expressions with patient survival in breast and prostate cancer. PMID 40641097 · Physiol Rep · 2025-Jul The record is a retrospective biomarker/prognostic analysis using public genomic datasets. It is not an original report of a Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary time-to-event efficacy endpoint. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Feasibility Randomised Controlled Trial of a New Digital Intervention ('FRAME') to Promote Resilience in Women Treated for Primary Breast Cancer. PMID 40634264 · Psychooncology · 2025-Jul The study is a randomized, human, oncology (breast cancer) feasibility trial, but it is not eligible for the cohort because it is not a Phase III/IIIb or definitive Phase II/III trial, it does not involve a drug-containing intervention (it's a digital/CBT intervention), and it does not report a primary or key secondary time-to-event efficacy endpoint (outcomes are acceptability, feasibility, interpretation bias, resilience, mood, and quality of life). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Executive Dysfunction and Disability in SPMS: Predictive Value of the Frontal Assessment Battery in the UCLH MS-STAT2 Cohort. PMID 40631687 · Eur J Neurol · 2025-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML. PMID 40629154 · Ann Hematol · 2025-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Urodynamics tests for the diagnosis and management of male bladder outlet obstruction: long-term follow-up of the UPSTREAM non-inferiority RCT. PMID 40619891 · Health Technol Assess · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Melatonin for prevention of delirium in patients receiving mechanical ventilation in the intensive care unit: a multiarm multistage adaptive randomized controlled clinical trial (DEMEL). PMID 40608082 · Intensive Care Med · 2025-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer. PMID 40601896 · JCO Precis Oncol · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of Ethnicity on Breast Cancer Outcome: A Systematic Review and Meta-Analysis of Randomized Phase III Trials of the Last Decade. PMID 40591899 · JCO Glob Oncol · 2025-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial. PMID 40590327 · J Gynecol Oncol · 2025-Jul 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial. PMID 40590326 · J Gynecol Oncol · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of CKDB-501A in Treating Moderate-To-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center Phase III Trial. PMID 40586136 · J Cosmet Dermatol · 2025-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T-Cell Leukemia-Lymphoma. PMID 40579886 · Hematol Oncol · 2025-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer. PMID 40574381 · Future Oncol · 2025-Jul The record is a protocol for a Phase III randomized oncology trial with a drug intervention, but it is not a results report. It does not present any primary or secondary time-to-event efficacy data (e.g., Kaplan-Meier curves, hazard ratios). |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated Urinary Tract Infection. PMID 40552968 · NEJM Evid · 2025-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020. PMID 40552964 · NEJM Evid · 2025-Jul The record is a prospective observational cohort study (KBP-2020) comparing survival trends over time, not a randomized controlled trial of a specific drug intervention. Although publication types include 'Randomized Controlled Trial', the abstract and methods describe a non-interventional study, and the 'Randomized Controlled Trial' tag is likely a metadata error. It lacks explicit Phase III/IIIb or Phase II/III trial evidence, randomized assignment, or a drug-controlled experimental design. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial. PMID 40541214 · Lancet Oncol · 2025-Jul The study is a phase 3 randomized oncology trial with a drug intervention and an original result. However, the primary efficacy endpoint is a categorical response rate (complete response), not a time-to-event endpoint as required by the cohort criteria. Therefore, it is not eligible. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial. PMID 40540760 · ESMO Open · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial. PMID 40532361 · ESMO Open · 2025-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients with Essential Hypertension: A Phase III, Multicenter, Double-Blind, Parallel-Group, Randomised study. PMID 40527906 · J Hum Hypertens · 2025-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial. PMID 40523368 · Lancet Oncol · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Pimavanserin safety in adult and elderly patients with neuropsychiatric symptoms related to neurodegenerative disease: An open-label extension study. PMID 40518812 · J Alzheimers Dis · 2025-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial. PMID 40517778 · Lancet Oncol · 2025-Jul 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
B
|
旧查询独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial. PMID 40517603 · EBioMedicine · 2025-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Debate 3: Metastasis Directed Therapy in Oligometastatic Prostate Cancer. PMID 40516977 · Semin Radiat Oncol · 2025-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Debate 2: The Case for Focal External Beam Radiation Therapy Boost Over Brachytherapy Boost for Prostate Cancer. PMID 40516976 · Semin Radiat Oncol · 2025-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Tight competition for the first-line treatment of Hodgkin's lymphoma: a comprehensive review of practice-changing developments in recent years. PMID 40506833 · Expert Opin Biol Ther · 2025-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Long-acting oral weekly risperidone (LYN-005) for schizophrenia in the USA (STARLYNG-1): a multicentre, open-label, non-randomised phase 3 trial. PMID 40506209 · Lancet Psychiatry · 2025-Jul 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A randomized comparative study on maintenance gemcitabine versus supportive care in pleural mesothelioma. PMID 40501447 · Future Oncol · 2025-Jul The record describes a randomized controlled trial in oncology with a drug intervention and primary time-to-event efficacy endpoints (PFS, OS). However, the phase of the trial is not explicitly stated as Phase III/IIIb or Phase II/III in the provided title, abstract, publication types, or MeSH terms. The deterministic review signals 'phase3': false and 'phase3_publication_type': false. Without explicit phase evidence from the original report's metadata, the eligibility criterion 'phase3_or_definitive' cannot be established, leading to ineligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Action of Low-Temperature Plasma Radiofrequency Ablation in the Treatment of Early Glottic Carcinoma. PMID 40497713 · Altern Ther Health Med · 2025-Jul The study is a randomized controlled trial in oncology (glottic carcinoma) with original results, but it is excluded because it does not meet the phase III/IIIb or Phase II/III requirement (no phase information provided, likely Phase II or other), the intervention is a device (radiofrequency ablation) without a drug component, and the endpoints are not time-to-event (e.g., recurrence rate is reported but not as a time-to-event endpoint with Kaplan-Meier or HR; voice recovery, complications, mucosal smoothness are not time-to-event). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life in patients undergoing laparoscopic versus open hemihepatectomy: a secondary analysis of the ORANGE II PLUS randomised controlled, phase 3, superiority trial. PMID 40491830 · Lancet Reg Health Eur · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection in China: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial. PMID 40489986 · Lancet Respir Med · 2025-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Evaluation of Attractive Targeted Sugar Baits, a new outdoor vector control strategy against malaria: Results from a cluster randomised open-label parallel arm controlled trial in Southwestern Mali. PMID 40482859 · J Infect · 2025-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial. PMID 40482671 · Lancet Diabetes Endocrinol · 2025-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial. PMID 40482670 · Lancet Diabetes Endocrinol · 2025-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis. PMID 40482662 · Lancet HIV · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol. PMID 40467357 · Lancet Digit Health · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Video Versus Face-To-Face Preoperative Anaesthetic Assessment: The VIDFACE Trial-A Statistical Analysis Plan. PMID 40467292 · Acta Anaesthesiol Scand · 2025-Jul The record is a protocol for a non-oncology randomized trial assessing a preoperative assessment method, not a drug intervention, and lacks time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Integration of self-hypnosis in an enhanced recovery after surgery program in gynecologic oncology - A prospective randomized trial. PMID 40466319 · Gynecol Oncol · 2025-Jul Study is a randomized trial in gynecologic oncology but evaluates a non-drug intervention (self-hypnosis) and measures patient-reported pain and anxiety as primary/secondary endpoints, not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Population Cellular Kinetics of Idecabtagene Vicleucel in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma. PMID 40461939 · Clin Pharmacokinet · 2025-Jul The record describes a pharmacokinetic/cellular kinetics modeling study of ide-cel within a randomized trial (KarMMa-3). While the trial itself is randomized and the study mentions an association with PFS (time-to-event), the report is a secondary mechanistic analysis, not a primary or key secondary efficacy result report. The phase of the trial is not explicitly stated in the provided metadata, and the analysis does not present formal efficacy results for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Postoperative hypofractionated intensity-modulated radiation therapy in cervical cancer: prospective phase 2 trial (POHIM_RT study). PMID 40449127 · Gynecol Oncol · 2025-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Treatment of small cell lung cancer; advances and future prospects. PMID 40446464 · Respir Investig · 2025-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Advancing Remission in Severe Asthma With Benralizumab: Latest Findings, Current Perspectives and Future Direction. PMID 40444568 · Clin Exp Allergy · 2025-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |